Latest Biotech News

GSK’s Jemperli (dostarlimab) won accelerated FDA approval as a treatment for advanced rectal cancer with a specific genetic signature, extending an immunotherapy label that was previously limited...

Gilead reported that emvistegrast delivered higher clinical response rates than placebo in a Phase 2 ulcerative colitis study, positioning the oral a4b7 integrin inhibitor for Phase 3. In the...

Roche and Hansoh Pharmaceutical Group launched a second collaboration aimed at developing antibody-drug conjugates, expanding Roche’s ADC platform access and Hansoh’s pipeline monetization. The...

Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion in an all-cash deal, adding a late-stage rare hematology asset to its pipeline. Shareholders of Silence will receive $20.00 per...

Dana-Farber said researchers will present primary analysis data from the Phase 3 DeLLphi-305 trial of tarlatamab plus durvalumab versus durvalumab alone in extensive-stage small cell lung cancer...

FDA’s Digital Health Center of Excellence director Rick Abramson said GenAI-enabled tools will likely need to be assessed “like a physician,” placing algorithmic behavior inside a clinical...

Readily secured an $11 million Series A to build a compliance intelligence platform, according to the funding announcement. The round was led by Define Ventures with participation from Y...

Takara Bio USA and SPT Labtech partnered to automate next-generation sequencing library preparation workflows using SPT Labtech’s firefly liquid-handling platform. The agreement begins with...

Pando Bioscience is using generative AI paired with an ultra-high-throughput screening platform to accelerate enzyme engineering for industrial and pharmaceutical applications. CEO Will Cao said...

Genmab faced a looming revenue cliff as Darzalex patent expirations approach, while the company leans on three oncology assets for next readouts. A report highlighted that Epkinly’s late-stage...

GSK’s cancer immunotherapy Jemperli (dostarlimab) received an accelerated FDA approval for advanced rectal cancer patients with a specific genetic signature, expanding beyond the drug’s initial...

Genmab is positioning its next catalyst slate as its Darzalex revenue stream faces major patent-loss exposure. The company’s strategy hinges on late-stage and near-term readouts for multiple...

Gilead reported positive Phase 2 results for emvistegrast, delivering higher clinical response rates than placebo in moderately to severely active ulcerative colitis in the SWIFT trial. In the...

Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion in an all-cash transaction, adding a late-stage rare blood-cancer siRNA program to its pipeline. The purchase brings Divesiran,...

Hansoh Pharmaceutical struck a deal with Roche to develop a portfolio of antibody-drug conjugates, extending Roche’s reach into China-powered discovery and development execution. The arrangement...

Pfizer made a business decision to end a Phase 2 trial for an autoimmune drug program, leaving the asset’s future uncertain. The trial tested PF-06835375 in primary immune thrombocytopenia, with...

Readily raised $11 million in a Series A round to support its compliance intelligence platform, aimed at helping life sciences organizations manage regulatory and operational requirements. The...

Labcorp agreed to acquire BioReference Diagnostics assets in a $722 million deal, expanding laboratory testing operations across clinical and women’s health, urology, and corrections services. The...

Manufacturers are pressing for greater transparency in the 340B Drug Pricing Program, citing limits in visibility into product distribution paths and exposure across distribution-side and...

Researchers developed a Raman “barcode” approach to distinguish 20 SARS-CoV-2 variants and subvariants by capturing differences in RNA molecular architecture, rather than relying on sequencing...